Our portfolio
With an extensive partner network and exclusive rights to over £400m in cancer research each year, we're a powerful partner in the fight to conquer cancer.
Explore our cancer-focused portfolio and discover a broad range of opportunities related to drug development, licensing, data and investing.
13
new drugs marketed
79
start-ups formed
£600m+
revenue from royalties and IP
150+
active licences
Our therapeutic pipeline
We're accelerating ground-breaking discoveries into life-improving treatments through our robust and sustainable pipeline. Our therapeutic portfolio spans the entire drug discovery process, from early stage discovery through to first-in-human studies and beyond.
Explore some of our licensing opportunities
Novel Apelin (GPCR) receptor antagonist peptide
At lead compound stage, for use as a single agent or in combination treatment for Glioblastoma or other Apelin dependent tumour therapies. Available for licensing and co-development.
OPTIMAM mammography image database (OMI-DB)
A large curated and centralized database of 2D and 3D mammogram images with annotations and associated clinical data from multiple NHS Breast Cancer screening sites. Available for licencing by commercial and non-profit organizations.
Potent, selective and orally bioavailable series of small molecules inhibiting glutaminase, with superior developability. Available for co-development.
Using DNA sequencing data to determine T cell fraction in tumours to predict immunotherapy response and cancer prognosis. Available for licensing and co-development.
View all licensing opportunities
Our start-up portfolio
We've built an incredible assembly line for start-up companies to bring early-stage technologies out of the research lab and translate them into patient benefit.
To date, we've played a role in the creation of 79 start-ups, with our portfolio of existing companies raising in excess of £3bn in total capital.
CancerTools.org
CancerTools.org is a non-profit, global research tools collaborative where cancer researchers from over 180 institutes worldwide, contribute research tools and share knowledge to accelerate cancer research discoveries.
Data portfolio
We're helping to unlock the potential of this data by supporting researchers to improve the utility and accessibility of data, and establish secure, trusted, patient-approved data partnerships.
Discover our oncology-focused data projects available for licensing or collaboration.
Hear from PentaBind
Success story
TechBio company PentaBind is using generative AI to develop aptamers that could target previously undruggable human proteins.
"Our AI-driven technology streamlines the development process, identifying aptamers with multiple drug-like characteristics in one step, significantly reducing the time and cost needed to create effective therapeutics. For cancer patients, this means the potential for more targeted treatments that specifically attack cancer cells without harming healthy tissue."
-Rory Ryan, PentaBind CEO and co-founder
Our latest news
Interested in progressing world-leading cancer research?
We're looking to partner with pharma, biotech, investors, academia and more.